Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Autolus Therapeutics (Nasdaq: AUTL) granted inducement stock options totaling 113,650 ADS to 22 employees under its 2025 Inducement Plan, with a grant date of January 26, 2026 and an exercise price of $1.46 per share. Each option has a 10-year term and vests over four years (25% after one year, then monthly over 36 months), subject to continued service. The awards were made as inducements in accordance with Nasdaq Listing Rule 5635(c)(4).

News Market Reaction

%

1 alert

% News Effect

On the day this news was published, AUTL declined NaN%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Inducement options: 113,650 ADSs Employees granted: 22 employees Exercise price: $1.46 per share +5 more

8 metrics

Inducement options 113,650 ADSs Stock options granted under 2025 Inducement Plan

Employees granted 22 employees Recipients of inducement stock option awards

Exercise price $1.46 per share Equal to AUTL closing price on Jan 23, 2026

Option term 10 years Maximum life of each inducement stock option

Vesting cliff 25% after 1 year Initial vesting on first anniversary of grant date

Remaining vesting 36 monthly installments Remainder vests over subsequent three years

Current price $1.38 Pre‑news share price vs $1.46 option strike

52-week range $1.105–$2.70 Price sits 48.89% below 52-week high

Market Reality Check

Price: $1.32 Vol: Volume 1,212,590 is 0.56x...

low vol

$1.32 Last Close

Volume Volume 1,212,590 is 0.56x the 20-day average of 2,171,830, indicating lighter-than-usual trading ahead of this HR-related news. low

Technical Shares at $1.38 are trading below the 200-day MA of $1.72 and about 48.89% under the 52-week high of $2.70.

Peers on Argus

AUTL was flat over the last 24h while peers were mixed: ADCT -0.76%, BNTC +1.29%...

AUTL was flat over the last 24h while peers were mixed: ADCT -0.76%, BNTC +1.29%, CGEM +3.93%, YMAB +0.23%, AURA +1.54%. No clear sector-wide move tied to this inducement grant.

Historical Context

5 past events · Latest: Jan 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 12	Prelim 2025 revenue	Positive	-17.1%	Preliminary AUCATZYL revenue, 2026 guidance and cash runway into Q4 2027.
Jan 06	Manufacturing collaboration	Positive	+7.5%	Plan to evaluate Cellares Cell Shuttle automated platform for AUCATZYL manufacturing.
Dec 08	CARLYSLE lupus data	Positive	+2.6%	Updated Phase 1 srSLE data and selection of 50M cells as Phase 2 dose.
Dec 08	Pediatric B-ALL data	Positive	+2.6%	High ORR and CR rates plus supportive real‑world safety data for obe‑cel.
Dec 01	Board appointment	Positive	-2.1%	Appointment of Ryan Richardson with capital markets and M&A experience.

Pattern Detected

Recent news with strong fundamental or clinical positives has produced mixed reactions: several clinical/manufacturing updates aligned positively, while major revenue/guidance and governance items saw negative divergence.

Recent Company History

Over the last few months, Autolus has reported key commercial and clinical milestones. On Jan 12, 2026, it disclosed preliminary AUCATZYL® revenues and 2026 guidance, yet shares fell despite the growth outlook. Earlier in January, a collaboration to evaluate automated manufacturing drew a positive reaction. December 2025 featured favorable CARLYSLE and pediatric B-ALL data with modest gains, while a board appointment on Dec 1, 2025 saw a small decline. Today’s inducement-option grants fit into ongoing scaling of the commercial organization.

Market Pulse Summary

This announcement details inducement stock option grants covering 113,650 ADSs to 22 new employees a...

Analysis

This announcement details inducement stock option grants covering 113,650 ADSs to 22 new employees at an exercise price of $1.46, vesting over four years. It follows recent milestones in revenue growth, manufacturing strategy, and clinical data. The grants align with ongoing scaling of Autolus’ commercial operations. Investors may watch future disclosures on hiring, operating performance, and additional equity awards to gauge how workforce expansion supports the company’s commercial and clinical objectives.

Key Terms

nasdaq listing rule 5635(c)(4), american depositary shares, stock option, exercise price, +1 more

5 terms

nasdaq listing rule 5635(c)(4) regulatory

"inducement material to the individual becoming an employee of Autolus in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

american depositary shares financial

"granted stock option awards to purchase an aggregate of 113,650 American Depositary Shares, representing an equal number of ordinary shares"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

stock option financial

"granted stock option awards to purchase an aggregate of 113,650 American Depositary Shares"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"an exercise price of $1.46 per share, which is equal to the closing price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"Each option has a ten-year term and vests over four years, with 25% of the original number of shares vesting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. Not financial advice.

LONDON and GAITHERSBURG, Md., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Compensation Committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 113,650 American Depositary Shares, representing an equal number of ordinary shares, to 22 employees pursuant to the Company’s 2025 Inducement Plan. The stock options were granted as an inducement material to the individual becoming an employee of Autolus in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have a grant date of January 26, 2026, and an exercise price of $1.46 per share, which is equal to the closing price of Autolus’ common stock on January 23, 2026. Each option has a ten-year term and vests over four years, with 25% of the original number of shares vesting on the one-year anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter, subject to the employee's continued service with Autolus through the applicable vesting dates.

About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL^®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.

Contact:  

Amanda Cray 
Executive Director, Investor Relations & External Communications
+1 617-967-0207 
a.cray@autolus.com 

FAQ

What did Autolus (AUTL) announce on February 4, 2026 about inducement stock options?

Autolus announced inducement grants of 113,650 ADS to 22 employees with a $1.46 exercise price. According to Autolus, the options were granted January 26, 2026 and vest over four years with a ten-year term.

How do the inducement options for AUTL vest and what is the exercise price?

The options vest 25% after one year, then monthly over 36 months, and have a 10-year term. According to Autolus, the exercise price is $1.46, equal to the January 23, 2026 closing price.

Why did Autolus grant stock options under Nasdaq Listing Rule 5635(c)(4)?

Autolus granted the awards as inducements to new employees in accordance with Nasdaq rules. According to Autolus, the grants were made as material inducements to employment under Rule 5635(c)(4).

How many employees received inducement awards from Autolus and how many shares are covered?

Autolus granted inducement options to 22 employees covering an aggregate of 113,650 ADS. According to Autolus, each ADS represents one ordinary share for purposes of the award count.

What are the potential shareholder effects of Autolus' inducement grants (AUTL)?

The grants increase outstanding option rights by 113,650 ADS, which may modestly dilute shareholders if exercised. According to Autolus, the awards are standard inducement grants subject to vesting and exercise terms.